Related Experiment Videos
YKL-40: a potential biomarker for osteoarthritis
1Department of Orthopaedics, Second Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China.
The Journal of International Medical Research
|February 14, 2009
Summary
YKL-40, a biological marker, shows promise for assessing osteoarthritis (OA) treatments. Its levels in joint tissues and fluids correlate with OA severity and disease activity, potentially aiding therapy development.
Area of Science:
- Biochemistry
- Biomarkers
- Osteoarthritis Research
Background:
- Current osteoarthritis (OA) treatments manage pain and inflammation but do not halt cartilage damage or disease progression.
- Biological markers offer a means to rapidly assess treatment efficacy in joint tissues.
Purpose of the Study:
- To review recent data on YKL-40 and its relationship with osteoarthritis.
- To explore YKL-40's potential as a biomarker for OA assessment and therapy development.
Main Methods:
- Review of current literature on YKL-40 in osteoarthritis.
- Analysis of YKL-40 levels in serum, synovial fluid, cartilage, and synovium of OA patients.
- Correlation of YKL-40 levels with histopathological changes and disease severity.
Main Results:
- YKL-40 presence in OA cartilage and synovium correlates with histopathological changes and local disease activity.
- Serum and synovial fluid YKL-40 levels correlate with OA disease severity.
- YKL-40 production by chondrocytes may modulate inflammatory responses and limit connective tissue degradation.
Conclusions:
- YKL-40 is a potential biomarker for assessing osteoarthritis progression and treatment response.
- Further research into YKL-40's functional roles may facilitate the development of novel OA therapies.